Background: Adherence to guideline-indicated care for the treatment of non-ST-elevation myocardial infarction (NSTEMI) is associated with improved outcomes. We investigated the extent and consequences of non-adherence to guideline-indicated care across a national health system. Methods: A cohort study (ClinicalTrials.gov identifier: NCT02436187) was conducted using data from the Myocardial Ischaemia National Audit Project (n = 389,057 NSTEMI, n = 247 hospitals, England and Wales, 2003-2013). Accelerated failure time models were used to quantify the impact of non-adherence on survival according to dates of guideline publication. Results: Over a period of 1,079,044 person-years (median 2.2 years of follow-up), 113,586 (29.2%) NSTEMI patients died. Of those eligible to receive care, 337,881 (86.9%) did not receive one or more guideline-indicated intervention; the most frequently missed were dietary advice (n = 254,869, 68.1%), smoking cessation advice (n = 245,357, 87.9%), P2Y12 inhibitors (n = 192,906, 66.3%) and coronary angiography (n = 161,853, 43.4%). Missed interventions with the strongest impact on reduced survival were coronary angiography (time ratio: 0.18, 95% confidence interval (CI): 0.17-0.18), cardiac rehabilitation (time ratio: 0.49, 95% CI: 0.48-0.50), smoking cessation advice (time ratio: 0.53, 95% CI: 0.51-0.57) and statins (time ratio: 0.56, 95% CI: 0.55-0.58). If all eligible patients in the study had received optimal care at the time of guideline publication, then 32,765 (28.9%) deaths (95% CI: 30,531-33,509) may have been prevented. Conclusion: The majority of patients hospitalised with NSTEMI missed at least one guideline-indicated intervention for which they were eligible. This was significantly associated with excess mortality. Greater attention to the provision of guideline-indicated care for the management of NSTEMI will reduce premature cardiovascular deaths.
Introduction
Cardiovascular disease is the main cause of death in Europe, with coronary heart disease accounting for 20% (1.8 million) of all deaths in Europe annually. 1 Associated productivity losses, direct health care costs and informal care due to mortality and morbidity cost the European Union economy €60 billion a year. 2 In America, non-ST-elevation myocardial infarction (NSTEMI) and unstable angina are the leading causes of hospitalisation. 3 Moreover, the global burden of NSTEMI persists despite substantial improvements in its treatment. 4, 5 Among patients hospitalised with NSTEMI, survival is better for those who receive timely guideline-indicated care. 4, 6 A number of cohort studies have shown that improving adherence to evidence-based interventions reduces the risk of death after NSTEMI. [7] [8] [9] International guidelines for the management of NSTEMI advocate a series of hospitalbased interventions supported by evidence from trials and observational data. 10, 11 Even so, a large proportion of patients fail to receive appropriate care. In a study of 5353 patients with acute myocardial infarction (AMI), optimal medical therapy was not provided to almost half. 12 Another study of patients with AMI found that of those who were eligible for nine evidence-based interventions, 50.6% missed at least one. 13 Thus far, however, studies concerning the relationship between mortality and care for AMI have been based on select cohorts, limited through non-contemporaneous, administrative or insurance-based databases. 7, 12, 14 None has specifically studied NSTEMI, arguably the most vulnerable of AMI phenotypes, 15 and none quantified the avoidable harm associated with suboptimal implementation of care across a single health system. Consequently, the excess of deaths associated with the degree of non-adherence to guideline-indicated care for NSTEMI is not known. In order to address this, we used data from the UK national heart attack register (Myocardial Ischaemia National Audit Program (MINAP)), which collects data from one health system (the National Health Service (NHS)) including all hospitals in England and Wales.
Methods

Setting and design
The analyses were based on data from MINAP, a comprehensive registry of acute coronary syndrome hospitalisations mandated by the Department of Health. 16 The analytical cohort (n = 389,057) was drawn from 441,945 patients with NSTEMI admitted to one of 247 hospitals between January 1, 2003, and June 30, 2013. Patients were eligible for the study if they were ⩾18 years of age. The discharge diagnosis was used to identify patients with NSTEMI. For patients with multiple admissions, the earliest record was used (to reduce potential biases due to previous treatment of multiple events). We excluded 31,321 (7.1%) patients because they died in hospital (and we could not therefore accurately ascertain their receipt of pharmacological therapies) and 21,567 (4.9%) patients due to missing mortality data ( Figure 1 ). Patient-level data concerning demographics, cardiovascular risk factors, medical history and clinical characteristics at the time of hospitalisation were extracted. Ethical approval for this study was not required under NHS research governance arrangements. The National Institute for Cardiovascular Outcomes Research (NICOR), which includes the MINAP database (Ref: NIGB: ECC 1-06 (d)/2011), had support under section 251 of the NHS Act 2006 to use patient information for medical research without consent. The study was conducted in compliance with the Declaration of Helsinki.
Guideline-indicated interventions
The European Society of Cardiology (ESC) guidelines for the management of NSTEMI and ESC Expert Consensus Documents were mapped to MINAP data in order to identify guideline-indicated interventions as they became available over the study period (Supplementary Section 1). The data contained information corresponding to the following 13 interventions: electrocardiogram, prescription of aspirin acutely, P2Y12 inhibitors at discharge, aspirin at discharge, beta-blockers at discharge in patients with left ventricular systolic dysfunction, angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) in patients with left ventricular systolic dysfunction, a HMG-CoA reductase enzyme inhibitors (statins), in-hospital use of aldosterone antagonist in patients with left ventricular systolic dysfunction and either diabetes or heart failure without significant renal dysfunction, echocardiogram, use of early invasive procedures (coronary angiography), smoking cessation advice, dietary advice and enrolment into a cardiac rehabilitation programme. 10 We used the adjusted mini-Global Registry of Acute Coronary Events (GRACE) risk score 17 to categorise NSTEMI as lowest (⩽70), low (71-87) and intermediate to high risk (>88) in line with National Institute for Health and Care Excellence (NICE) guidance. 18 We quantified receipt of care only for patients who were deemed eligible for each treatment according to ESC guidelines. Patients were also classified as ineligible if a treatment was contraindicated, not indicated, not applicable, if the patient declined treatment as recorded in MINAP or if the patient was hospitalised prior to the time that the treatment was recommended by the guidelines.
Survival analysis
Multilevel accelerated failure time models were used to identify the association between missed guideline-indicated interventions and time to all-cause mortality (Supplementary Section 3). All models included a shared frailty term to account for the clustering of patients within hospitals. Models were adjusted for case mix using the adjusted 6-month mini-GRACE risk score and for baseline patient characteristics, including previous history of AMI, angina, diabetes, hypertension, peripheral vascular disease, a family history of coronary heart disease, chronic obstructive pulmonary disease, hypercholesterolaemia and previous coronary revascularisation. Missing data were imputed using multiple imputation by chained equations for missing GRACE covariates and a default imputation strategy based on clinical expert opinion was implemented for selected treatment variables (Supplementary Section 2). Imputation results were checked for reliability and consistency using Monte Carlo estimates and through comparison with complete case analysis (Supplementary Section 3). Parameter estimates were expressed as time ratios (TRs) and 95% confidence intervals (CIs) pooled over the ten imputations. A TR of ⩽1 indicates reduced expected survival time and therefore worse survival associated with the missed guideline-indicated intervention.
Excess deaths
For each patient, a score was derived by dividing the total number of interventions received by the total number of interventions that the patient was eligible for. The score was categorised into optimal care (all interventions received) or not (suboptimal care). Using optimal care as the reference, the dichotomised score was regressed on time to death/censorship. The resultant adjusted TR was multiplied by the 1-year mortality rate and by the proportion of patients in the suboptimal category. The product was then multiplied by the total number of NSTEMI cases between 2003 and 2013 (Supplementary Section 4). As a sensitivity analysis, we used latent class analysis to model the interactions of all 13 guidelineindicated interventions with survival (Supplementary Section 5). Briefly, latent class analysis (LCA) is a statistical method that identifies underlying subgroups of individuals based on observed characteristics. Three subgroups of care (latent classes) were identified, which represented homogenous patterns of the probability of receipt of care. The classes were then regressed on time to death/censorship and the adjusted TRs multiplied by the 1-year mortality rate for the corresponding class and by the proportion of patients in that class. This figure was then multiplied by the total number of NSTEMI cases between 2003 and 2013.
Results
Of 389,057 patients with NSTEMI (mean age 70.9 (SD 13.3) years, 63.1% male), the majority (93.3%) were white, a third (31.5%) had angina and a quarter (24.9%) had previous AMI (Table 1) . Over half (71.8%) were smokers ever/ current, 48.5% had hypertension, 20.9% had diabetes and 14.6% had asthma or chronic obstructive pulmonary disease. Over 2% of patients had an admission systolic blood pressure of <90 mmHg. About half (56.8%) of all electrocardiographic changes were ST-segment deviation or T-wave inversion, with 15.7% of patients having no acute changes. According to the mini-GRACE risk score, eight out of ten patients were at intermediate or high risk.
Guideline-indicated interventions
Only 51,176 (13.2%) patients received all of the interventions for which they were eligible and 337,881 (86.9%) did not receive one or more guideline-indicated intervention. The most frequently missed interventions were dietary advice (n = 254,869, 68.1%), smoking cessation advice (n = 245,357, 87.9%), echocardiography (n = 193,483, 49.7%), P2Y12 inhibitors at discharge from hospital (n = 192,906, 66.3%), coronary angiography (n = 161,853, 43.4%) and in-hospital aspirin (n = 106,407, 45.0%) ( Table  2 ). Figure 2 depicts the increases from 2003 to 2013 in all guideline-indicated interventions, except for pre-hospital use of an electrocardiogram and pre-hospital aspirin, which both decreased.
Patterns of care
Using latent class analysis, we identified three patterns of care and nominally labelled them 'high', 'intermediate' and 'low'. Patients in the high latent class were distinguishable from other classes by their high probabilities for receipt of P2Y12 inhibitors (0.72), echocardiography (0.60), cardiac 
Excess deaths
If all study patients with NSTEMI had received the guideline-recommended care for which they were eligible, then 32,765 ( 
Discussion
This study quantified the excess mortality associated with non-adherence to international (ESC) guideline-recommended care for patients hospitalised with NSTEMI across a single health care system (the NHS of England and Wales) over the last decade. We found that if all patients during the study period had received the investigations and treatments for which they were eligible, according to the time of publication of the guidelines, then approximately 33,000 deaths may have been prevented. This equates to over a quarter of all NSTEMI deaths or approximately one avoidable death per month per hospital over the last decade. The care groupings that were most frequently missed were dietary and smoking cessation advice, echocardiography to evaluative left ventricular systolic function, the prescription of P2Y12 inhibitors, coronary angiography and the acute prescription of aspirin. We found that all of the 13 care interventions, if missed (except aldosterone antagonists), had significant and strong associations with reduced survival, particularly coronary angiography, cardiac rehabilitation, smoking cessation and the use of statins. Whilst we identified substantial improvements in care over the decade of study, in the latter years of study, a third of NSTEMI patients still did not receive treatments for which they were eligible. Moreover, we noted (as we did in our earlier research) that patients who had low probabilities for receipt of pharmacological interventions also missed the opportunity to receive counselling interventions. 13 The management of NSTEMI is supported by rigorous data from many randomised controlled trials. 10, 11 Advances in treatments for NSTEMI are reported in high-impact publications and are summarised in international guidelines, which are frequently updated as new evidence emerges. 10, 11 The underlying assumption is that this evidence is then translated into practice. Internationally, this has been summarised by several registries that report temporal improvements in care 5, 19, 20 and a global decline in mortality from cardiovascular disease. The management of patients with NSTEMI, however, is multifaceted and comprises a complex journey, starting from a call for help to a range of hospital interventions and cardiac rehabilitation; hence, there are many opportunities whereby care could be missed. Our investigation shows that national registry data allow higher-resolution investigation of sequential care deficits that are significantly associated with premature cardiovascular death to be identified in seemingly 'wellfunctioning' health care systems. Addressing these cumulative care gaps will save lives.
We found that many care interventions were frequently not provided subsequent to their recommendation in international guidelines. In England and Wales, over 40,000 people per year are hospitalised with NSTEMI, suggesting that the opportunity to reduce death following NSTEMI is determined by supply factors and not its demand, yet the national health care system that was studied did not appear to enable all patients to have an equal chance of receiving specialist cardiac investigations and treatments. The care most frequently missed was that with the greatest potential to reduce death; not receiving coronary angiography was associated with a reduction in time to death of 82% and not receiving cardiac rehabilitation of 51%, whereas not receiving smoking cessation advice was associated with halving of the time to death, and missing P2Y12 inhibitors was associated with a 24% reduction. In part, this is likely to be due to constraints regarding the availability of specialists and associated equipment, but also perhaps because of the heterogenic approach to the management of patients with NSTEMI, which compares with the management of ST-elevation myocardial infarction 10 that, for the NHS, is institutionally operationalised through a national primary PCI programme. [21] [22] [23] By contrast, the decision to prescribe evidence-based medications or to proceed to coronary angiography is determined at the level of the physician in a nonemergent setting.
Our labels of high, intermediate and low receipt of care aided with the interpretation of our latent class analysis. In reality, however, the classes were representative of more complex patient patterns of care, rather than all patients receiving either high, intermediate or low levels of care. Patients in the high class had low probabilities for the receipt of ACEis/ARBs and beta-blockers. Whilst this seems incongruous, these patients did not have left ventricular systolic dysfunction and therefore these pharmacological medications were not indicated. In effect, high latent class patients were healthier and more likely to receive evidence-based care, confirming the findings from others who have shown that the patients who are most likely to receive guideline-indicated treatments tend to be the lower-risk patients. [24] [25] [26] This study has implications for international cardiovascular health. In line with the World Health Organisation Global Action Plan for non-communicable disease, we identify where in a modern health care system the provision of essential treatments is required in order to reduce premature death. 27 Our results may, therefore, be extrapolated to other developed and developing countries that lag behind Northern Europe and North America in their provision of care, 28, 29 and where greater gains in cardiovascular health maybe realised. We clearly show that, across a modern health care system such as in the UK, there are substantial opportunities to improve outcomes through relatively simple measures, such as ensuring that all patients with NSTEMI receive appropriate guideline-indicated care.
Our study has strengths in that it evaluates care across a single health care system, is population-based and accesses a clinical registry that is designed specifically to evaluate quality of heart attack care. There are no other databases of comparable size, coverage and quality that include all hospitals within a country. However, our study has limitations: 1) we were reliant upon the accurate recording of data. 2) MINAP does not collect all cases of NSTEMI -our study was designed to study the impact of missed care at the level of the patient and not the numbers of NSTEMI patients who were hospitalised. We speculate that MINAP captures less than half of all NSTEMI cases in England and Wales; consequently, the number of preventable deaths that we report will be underestimated. 3) The deficits in care for smoking cessation and dietary advice may be inflated because advice regarding smoking and diet are implicit in cardiac rehabilitation programmes, and there may have been preferencing by coders towards recording cardiac rehabilitation rather than counselling. 4) Missing data could have biased our estimates. We studied the nature of missing MINAP data and used, where necessary, imputation algorithms. The corresponding sensitivity analyses confirmed consistent results irrespective of the method adopted. 5) The investigation of ESC guideline-indicated care for NSTEMI was not able to extend to all class 1, level A recommendations for the management of NSTEMI. Thus, it is possible that the deficits and their consequences are greater than we report. For example, we had insufficient data to study the prescription of anticoagulants. 6) It is probable that other factors beyond the hospital stay (such as drug adherence, number of cardiac rehabilitation sessions attended and primary care visits) may also have influenced survival. 7)
We studied all-cause mortality, when non-cardiovascular deaths may not be attributable to missed NSTEMI care. 30 8) Regarding the use of aldosterone antagonists, we found that application of the inclusion and exclusion criteria stated in international guidelines reduced the size of the exposed subgroup to such an extent that the resultant estimates were imprecise. 9) Although contraindication, refusal and non-applicability information was available in MINAP, additional reasons for those recorded simply as not having received care interventions were not available. 10) This observational study cannot demonstrate causation, although optimal adjustment was made for confounders based on the available information in the study dataset and as informed by external information from other studies.
Conclusion
This first national study of the pathway of care for NSTEMI has identified substantial gaps in the provision of guidelineindicated interventions as recommended by the ESC. Such deficits in care, cumulatively, were significantly associated with many premature cardiovascular deaths when compared with patients who were eligible for and received guideline-indicated care -approximately a third of the deaths may have been preventable. Whilst cardiovascular care has substantially improved in modern health care systems with resultant reductions in mortality, only through higher-resolution investigations using whole healthcare system clinical registries can modifiable deficits of care be identified and, therefore, addressed.
